NCT01094860View on ClinicalTrials.gov

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 8, 2010

Primary Completion Date

August 9, 2018

Study Completion Date

August 9, 2018

Conditions
Leukemia
Interventions
DRUG

Nelarabine

Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01094860 - Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies | Biotech Hunter | Biotech Hunter